The effects of oral doses of lansoprazole and omeprazole on gastric pH

被引:82
作者
Tolman, KG [1 ]
Sanders, SW [1 ]
Buchi, KN [1 ]
Karol, MD [1 ]
Jennings, DE [1 ]
Ringham, GL [1 ]
机构
[1] ABBOTT LABS,ABBOTT PK,IL 60064
关键词
proton pump inhibitors; lansoprazole; omeprazole; pharmacokinetics; pharmacodynamics; gastric pH; serum gastrin;
D O I
10.1097/00004836-199703000-00003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We compared gastric pH values after therapeutic doses of lansoprazole and omeprazole in 17 healthy adult men. The pharmacokinetics of the two drugs were studied. A three-way crossover design compared the effects on gastric pH of 15 and 30 mg lansoprazole and 20 mg omeprazole-each given once daily for 5 days. Ambulatory 24-h intragastric pH levels were measured before dosing, after the first and fifth doses in each period, and 15 days after each dosing period. A positive relationship between the lansoprazole or omeprazole area under the curve (AUCs) and the 24-h mean pH values was found for each regimen. No differences in maximum concentration (C-max) and AUC were noted from day 1 to day 5 for the two lansoprazole doses. With omeprazole, both C-max and AUC levels were greater on day 5 than on day 1. All three regimens increased 24-h mean gastric pH, although 30 mg lansoprazole had the most significant effect. The percentage of time that gastric pH was >3, >4, and >5 was also significantly higher with 30 mg lansoprazole. All three regimens were associated with reversible elevations of serum gastrin, which more than doubled at some points. No clinically significant adverse events were documented.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 50 条
  • [21] Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans
    Katashima, M
    Yamamoto, K
    Tokuma, Y
    Hata, T
    Sawada, Y
    Iga, T
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1998, 23 (01) : 19 - 26
  • [22] Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole
    Sharma, VK
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1999, 56 : S18 - S21
  • [23] The effects of omeprazole on intragastric pH, intestinal motility, and gastric emptying rate
    Rasmussen, L
    Oster-Jorgensen, E
    Qvist, N
    Pedersen, SA
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1999, 34 (07) : 671 - 675
  • [24] Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes
    DiGiacinto, JL
    Olsen, KM
    Bergman, KL
    Hole, EB
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (05) : 600 - 605
  • [25] HPLC Analysis for omeprazole and lansoprazole in blood plasma
    Miroshnichenko I.I.
    Yurchenko N.I.
    Pharmaceutical Chemistry Journal, 2002, 36 (7) : 389 - 391
  • [26] Comparison of oral esomeprazole and oral omeprazole in the treatment of equine squamous gastric disease
    Sundra, Tania
    Gough, Sarah
    Rossi, Gabriele
    Kelty, Erin
    Rendle, David
    EQUINE VETERINARY JOURNAL, 2024, 56 (05) : 952 - 958
  • [27] Anaphylaxis to lansoprazole with tolerance to omeprazole
    Aksu, K.
    Kurt, E.
    ALLERGOLOGIA ET IMMUNOPATHOLOGIA, 2012, 40 (06) : 393 - 394
  • [28] Comparative effectiveness of different recommended doses of omeprazole and lansoprazole for gastroesophageal reflux disease: a meta-analysis of published data
    Liu, Feng
    Wang, Jing
    Wu, Hailong
    Wang, Hui
    Wang, Jianxiang
    Zhou, Rui
    Zhu, Zhi
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (04): : 4089 - 4098
  • [29] Effects of long-term treatment with lansoprazole and omeprazole an serum gastrin and the fundic mucosa
    Villarino, A
    Arbeloa, L
    Diaz, E
    deRetana, OF
    Samitier, S
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 1997, 89 (05) : 352 - 356
  • [30] Effect of gastric pH on erlotinib pharmacokinetics in healthy individuals: omeprazole and ranitidine
    Kletzl, Heidemarie
    Giraudon, Mylene
    Ducray, Patricia Sanwald
    Abt, Markus
    Hamilton, Marta
    Lum, Bert L.
    ANTI-CANCER DRUGS, 2015, 26 (05) : 565 - 572